|
NZ506839A
(en)
*
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
USRE46830E1
(en)
|
2004-10-19 |
2018-05-08 |
Polypeptide Laboratories Holding (Ppl) Ab |
Method for solid phase peptide synthesis
|
|
PT1877435E
(pt)
|
2005-05-04 |
2011-05-24 |
Zealand Pharma As |
An?logos de p?ptido-2 semelhante a glucagon
|
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
|
EP1975142A4
(en)
*
|
2005-11-22 |
2009-12-02 |
Univ Nihon |
AUTOMATED SOLID PHASE SYNTHESIS OF PYRROL-IMIDAZOLE POLYAMIDE
|
|
CA2634743C
(en)
|
2005-12-23 |
2014-07-29 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
|
KR100859972B1
(ko)
|
2006-02-20 |
2008-09-25 |
이화여자대학교 산학협력단 |
막투과 단백질 도메인 펩타이드
|
|
CN101437836B
(zh)
*
|
2006-03-29 |
2013-07-24 |
株式会社糖锁工学研究所 |
肽的硫酯化合物的制造方法
|
|
EP2051995B1
(en)
|
2006-11-08 |
2017-02-08 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
|
US8685919B2
(en)
|
2008-12-15 |
2014-04-01 |
Zealand Pharma A/S |
Glucagon analogues
|
|
US8642541B2
(en)
|
2008-12-15 |
2014-02-04 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EA020596B1
(ru)
|
2008-12-15 |
2014-12-30 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
AU2008365556A1
(en)
|
2008-12-15 |
2011-07-21 |
Zealand Pharma A/S |
Glucagon analogues
|
|
DK2454282T3
(en)
|
2009-07-13 |
2015-05-04 |
Zealand Pharma As |
acetylated glucagonanaloger
|
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
KR20130086343A
(ko)
|
2010-06-24 |
2013-08-01 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
KR20140043709A
(ko)
|
2011-01-20 |
2014-04-10 |
질랜드 파마 에이/에스 |
아실화 글루카곤 유사체와 인슐린 유사체의 조합
|
|
BR112014010780A2
(pt)
|
2011-11-03 |
2017-04-25 |
Zealand Pharma As |
conjugados do peptídeo agonista do receptor glp-1-gastrina
|
|
SG11201403377QA
(en)
|
2011-12-23 |
2014-07-30 |
Zealand Pharma As |
Glucagon analogues
|
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
|
WO2013113916A2
(en)
|
2012-02-03 |
2013-08-08 |
Zealand Pharma A/S |
Ghrelin analogues
|
|
JP6228187B2
(ja)
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
CA2902324A1
(en)
|
2013-03-12 |
2014-10-09 |
Molecular Templates, Inc. |
Cd20-binding immunotoxins for inducing cellular internalization and methods using same
|
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
EP2976325B1
(en)
|
2013-03-21 |
2017-03-01 |
Sanofi-Aventis Deutschland GmbH |
Synthesis of cyclic imide containing peptide products
|
|
HK1219477A1
(zh)
|
2013-03-21 |
2017-04-07 |
Sanofi-Aventis Deutschland Gmbh |
合成含有乙内酰脲的肽产物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
IL287490B
(en)
|
2014-01-27 |
2022-08-01 |
Molecular Templates Inc |
Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
|
|
MX2016011821A
(es)
|
2014-03-11 |
2017-04-27 |
Molecular Templates Inc |
Proteinas que comprenden regiones efectoras de subunidad a de toxina shiga proximas a amino terminal y regiones de union de tipo inmunoglobulina de direccionamiento selectivo celular.
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
CN113831416A
(zh)
|
2014-06-11 |
2021-12-24 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
CA2953569A1
(en)
|
2014-06-26 |
2015-12-30 |
Ossianix, Inc. |
Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
|
|
US10253078B2
(en)
|
2014-10-29 |
2019-04-09 |
Zealand Pharma A/S |
GIP agonist compounds and methods
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
ES2856457T3
(es)
|
2015-02-05 |
2021-09-27 |
Molecular Templates Inc |
Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
|
|
EA035791B1
(ru)
|
2015-03-18 |
2020-08-11 |
Зилэнд Фарма А/С |
Аналоги амилина
|
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|
|
CA2984635A1
(en)
|
2015-05-30 |
2016-12-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
EP3325510A2
(en)
|
2015-07-26 |
2018-05-30 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
JP2018530543A
(ja)
|
2015-09-17 |
2018-10-18 |
マサチューセッツ インスティテュート オブ テクノロジー |
固相ペプチド合成のための方法およびシステム
|
|
US11097010B2
(en)
|
2016-08-06 |
2021-08-24 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
US10071140B2
(en)
|
2016-09-09 |
2018-09-11 |
Zealand Pharma A/S |
Amylin analogues
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
EP4424320A3
(en)
|
2016-12-09 |
2025-06-11 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
RU2756011C2
(ru)
|
2016-12-09 |
2021-09-24 |
Зилэнд Фарма А/С |
Glp-1/glp-2 двойные агонисты
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
AU2018213194B2
(en)
|
2017-01-25 |
2023-01-12 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
|
|
WO2018229252A1
(en)
|
2017-06-16 |
2018-12-20 |
Zealand Pharma A/S |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
CA3080351A1
(en)
|
2017-11-02 |
2019-05-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
|
KR20200135797A
(ko)
|
2018-02-27 |
2020-12-03 |
제트피 에스피브이 3 케이/에스 |
콤프스타틴 유사체 및 이들의 의학적 용도
|
|
AU2019257343A1
(en)
|
2018-04-17 |
2020-09-10 |
Molecular Templates, Inc. |
HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
|
|
US12258414B2
(en)
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
IL280880B2
(en)
|
2018-08-27 |
2025-04-01 |
Regeneron Pharma |
Using Raman Spectroscopy in Downstream Purification
|
|
WO2020056327A1
(en)
|
2018-09-14 |
2020-03-19 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
CA3127624A1
(en)
|
2019-01-23 |
2020-07-30 |
Millennium Pharmaceuticals, Inc. |
Anti-cd38 antibodies
|
|
MX2021008790A
(es)
|
2019-01-23 |
2021-08-24 |
Millennium Pharm Inc |
Proteinas de union a cd38 que comprenden efectores de la subunidad a de la toxina shiga desinmunizada.
|
|
JP7580403B2
(ja)
|
2019-06-14 |
2024-11-11 |
ジーランド・ファーマ・ア／エス |
Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
|
|
US20220306695A1
(en)
|
2019-08-27 |
2022-09-29 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
KR20220066095A
(ko)
|
2019-09-20 |
2022-05-23 |
질랜드 파마 에이/에스 |
Kv1.3 차단제
|
|
US20210155671A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
|
US20230110689A1
(en)
|
2020-03-30 |
2023-04-13 |
Zealand Pharma A/S |
Agonist combination
|
|
WO2021198196A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
JP2023538807A
(ja)
|
2020-07-16 |
2023-09-12 |
セッドぺー エスぺーヴェー ３ カー／エス |
補体因子ｃ３の阻害剤及びそれらの医学的使用
|
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
|
EP4262745B1
(en)
|
2020-12-16 |
2025-01-29 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
JP2023553563A
(ja)
|
2020-12-16 |
2023-12-22 |
ジーランド ファーマ エー／エス |
Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
|
|
EP4262747A1
(en)
|
2020-12-16 |
2023-10-25 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
US20240316155A1
(en)
|
2021-02-18 |
2024-09-26 |
Zealand Pharma A/S |
Composition for treating short bowel syndrome
|
|
EP4308242A1
(en)
|
2021-03-17 |
2024-01-24 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
JP2024511449A
(ja)
|
2021-03-23 |
2024-03-13 |
ジーランド ファーマ エー／エス |
Ｋｖ１．３遮断薬
|
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
|
US20240279298A1
(en)
|
2021-06-18 |
2024-08-22 |
Beijing Tuo Jie Biopharmaceutical Co. Ltd. |
Glucagon analog and medical use thereof
|
|
US20250122298A1
(en)
|
2021-08-17 |
2025-04-17 |
Ossianix, Inc. |
Deimmunized vnar domains and scaffolds
|
|
MX2024002600A
(es)
|
2021-09-03 |
2024-03-22 |
Zealand Pharma As |
Regimen de dosificacion.
|
|
KR20240111800A
(ko)
|
2021-12-01 |
2024-07-17 |
질랜드 파마 에이/에스 |
인터루킨-23 수용체의 펩티드 억제제
|
|
TW202421654A
(zh)
|
2022-09-28 |
2024-06-01 |
丹麥商西蘭製藥公司 |
治療肥胖之方法
|
|
EP4604984A1
(en)
|
2022-10-18 |
2025-08-27 |
Zealand Pharma A/S |
Inhibitors
|
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|
|
EP4471048A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4471049A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2025056677A1
(en)
|
2023-09-15 |
2025-03-20 |
Zealand Pharma A/S |
Dasiglucagon for use in the treatment of congenital hyperinsulinism
|
|
WO2025120001A1
(en)
|
2023-12-04 |
2025-06-12 |
Zealand Pharma A/S |
Amylin analogues for reducing consumption of high-fat food
|
|
WO2025120002A1
(en)
|
2023-12-04 |
2025-06-12 |
Zealand Pharma A/S |
Petrelintide for reducing weight whilst preserving lean mass
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
US20250381242A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Antimicrobial peptides against citrus greening
|
|
US20250382332A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Novel alpha-factor based peptides with antifungal activity
|
|
WO2025262301A1
(en)
|
2024-06-20 |
2025-12-26 |
Zealand Pharma A/S |
Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
|
|
WO2026003546A1
(en)
|
2024-06-27 |
2026-01-02 |
Vrg Miniprotein Zrt |
Potassium ion kv1.3 channel inhibitors
|
|
WO2026013260A1
(en)
|
2024-07-12 |
2026-01-15 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|